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Multiple drug intolerance to antihypertensive medications
(MDI-HTN) is an overlooked cause of nonadherence. In this
study, 55 patients with MDI-HTN were managed with a
novel treatment algorithm utilizing sequentially initiated
monotherapies or combinations of maximally tolerated
doses of fractional tablet doses, liquid formulations, trans-
dermal preparations, and off-label tablet medications. A
total of 10% of referred patients had MDI-HTN, resulting in
insufficient pharmacotherapy and baseline office blood
pressure (OBP) of 17824/9415 mm Hg. At baseline,
patients were intolerant to 7.63.6 antihypertensives; they
were receiving 1.41.1 medications. After 6 months on the
novel MDI-HTN treatment algorithm, both OBP and home
blood pressure (HBP) were significantly reduced, with
patients receiving 2.01.2 medications. At 12 months,
OBP was reduced from baseline by 175/93 mm Hg
(P<.01, P<.05) and HBP was reduced by 115/12
3 mm Hg (P<.01 for both) while patients were receiving
1.91.1 medications. Application of a stratified medicine
approach allowed patients to tolerate increased numbers of
medications and achieved significant long-term lowering of
blood pressure. J Clin Hypertens (Greenwich). 2016;18:129–
138. ª 2015 The Authors. The Journal of Clinical Hypertension
published by Wiley Periodicals, Inc.
Hypertension is a major risk factor for cardiovascular
morbidity and mortality worldwide,1 for which man-
agement is based on two principal, complementary
approaches––lifestyle modification and lifelong adher-
ence to antihypertensive medication.2–4 Despite the
availability of numerous medication classes that lower
blood pressure (BP), hypertension is adequately con-
trolled to guideline-recommended levels in <50% of
treated patients.5 Numerous factors may contribute to
suboptimally controlled BP levels, including failure to
adopt proven lifestyle interventions,6 secondary forms
of hypertension,7 treatment-refractory hypertension,8
and physician inertia.9
A further patient-related factor that is increasingly
recognized as a contributory cause of failure to attain BP
control is imperfect (or non-) adherence to prescribed
medication;10,11 only 50% of hypertensive patients
persist with antihypertensive medications after
12 months.12,13 Techniques to identify such patients
with directly observed therapy followed by ambulatory
BP (ABP)14 or with analytical drug (or drug metabolite)
measurement in both urine and plasma have recently
demonstrated high levels of partial (or total) covert
nonadherence to prescribed medications in difficult-to-
treat hypertensive patients.15,16 Causes of imperfect
adherence can be patient related (lack of understanding
of cardiovascular [CV] disease risk factors or reluctance
to take lifelong medication), physician related (insuffi-
cient time/resources, incorrect assumption of patient
education about CV disease), or medication related
(high dosing frequency, polypharmacy, adverse drug
reactions [ADRs]).17,18 Many of these issues can be
targeted by combining personalized, intensified, patient-
focused programs and simplified dosing regimens,
including fixed-dose combinations.19,20 However, an
overlooked cause of poor adherence, that is not
amenable to the interventions listed above, is multiple
drug intolerances (overt nonadherence), which prevents
sufficient pharmacotherapy to achieve BP control.
Achieving optimal adherence in patients with hyper-
tension is challenging. Patients are generally asymp-
tomatic and therefore unlikely to choose to tolerate
medications that make them feel in any way worse than
their baseline state, especially as common ADRs related
to antihypertensive therapy include sexual and cognitive
dysfunction. Furthermore, the taking of medication for
primary prevention only serves to reduce a frequently
distant risk of future events thereby removing the
positive reinforcement aspect of disease-recurrence
avoidance. Regardless of the cause, if ADRs are
distressing and incapacitating enough to significantly
affect quality of life and warrant discontinuation of
therapy, then they pose a particular therapeutic chal-
lenge in primary and specialist care. The patients
inevitably are difficult to treat with very few treatment
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options, as there is no published evidence of an effective
treatment stratagem despite being at high CV risk as a
result of uncontrolled BP.
The term multiple drug intolerance (MDI) syndrome
has been used to describe patients who express ADRs to
three or more drugs of any class without a known
immunological mechanism.21 There has been little inter-
est in such patients to date, evidenced by the lack of
acknowledgement, description, or definition of this group
in existing international guidelines.2–4 Furthermore, since
the publication of recent reports on device-based treat-
ments for resistant hypertension,22 we have seen increas-
ing referrals of patients with uncontrolled BP and
multiple drug intolerances to antihypertensive medica-
tion (MDI-HTN) toour clinic as both referring physicians
and patients now contemplate nonpharmacologic
approaches to difficult-to-treat hypertension. However,
these patients have been excluded from existing clinical
trials of device-based therapies as they most commonly
fail to tolerate more than three antihypertensive medica-
tions required for a traditional definition of resistant
hypertension,2–4 which is a core inclusion criterion of
existing device-based hypertension trials22–24 backed up
by recent international consensus guidelines.25.
We developed a medication-based, novel treatment
algorithm specifically for patients with MDI-HTN that
was initiated as part of routine care in our center. In this
study, we sought to determine the impact of our
algorithm in a cohort of MDI-HTN patients who were
referred for expert management or consideration of
entry into clinical trials of device-based interventions.
METHODS
We conducted a retrospective analysis of electronic and
paper records for patients referred to the Barts BP Centre
of Excellence for a 24-month period from July 2012
onwards. All patient-identifiable fields were removed
before analysis. This analysis was conducted as part of a
clinical effectiveness/quality improvement project and
received approval from the institutional review board.
Patients
Patients were defined as having MDI-HTN if they had a
documented history (at referral or new patient visit) of
intolerance to at least three unrelated classes of antihy-
pertensive medications (that resulted in not being
prescribed that particular medication any further) with
the result that patients were unable to take a conven-
tional guideline-based regimen of antihypertensives4
and therefore did not meet the conventional criteria of
resistant hypertension.2–4 Intolerances were included
irrespective of subtype (ie, if there were type 1 hyper-
sensitivity reactions, pharmacodynamically predictable
or pharmacodynamically unpredictable).
Patients were included for analysis if they had:
 MDI-HTN.
 Confirmed uncontrolled BP by 24-hour ABPmonitor-
ing (daytime mean, systolic BP [SBP] >135 mm Hg
and/or diastolic BP [DBP] >85 mm Hg).4
 Α minimum of three clinic visits (new patient +2
follow-up) with >6 months of follow-up.
 Complete medication/dose/formulation/posology
information for each visit.
 Complete clinic BP information for each visit.
 Existing use of home BP monitoring at referral, and
continued use for intervisit periods.
Exclusion criteria included hypertension <1 year
duration since diagnosis, and secondary cause of
hypertension.
Data Extraction
Once patients with MDI-HTN were identified, data
from electronic health records were extracted. Any
missing data were searched for manually in paper health
records, including:
 Demographics and anthropometric data.
 Reasons and mode for referral.
 Health-related lifestyle issues.
 Medical diagnoses, hypertensive target organ damage
(TOD), BP, and biochemical indices.
 Current (and previous) antihypertensive and other
drugs (medication/dose/formulation/posology).
Medication schedules between patientswere compared
by percentage of maximal licensed (or recommended)
dose (MLD) for hypertension as listed in pharmacopoeia
such as the British National Formulary.26 For medica-
tions such as spironolactone, that is recommended for use
in hypertension4 but is not licensed, and other medica-
tions that did not have a specific license for hypertension,
such as tadalafil, we decided on an appropriatemaximum
dose that we would not exceed in usual clinical practice
(Table I). For each patient, the sum of the percentage of
the MLD for each medicine gave a total whole medicine
equivalent (WME).
For example, a patient taking bendroflumethiazide
2.5 mg daily (MLD for hypertension 2.5 mg daily,
therefore 1.0 WME) and amlodipine 5 mg daily (MLD
10 mg daily, therefore 0.5 WME) has a total of 1.5
WME on two medications.
In contrast, a patient taking losartan 25 mg daily
(MLD 100 mg daily, therefore 0.25 WME) and biso-
prolol 5 mg (MLD 20 mg daily, therefore 0.25 WME)
has a total of 0.5 WME on two medications.
For comparison of baseline demographics and
characteristics, we randomly chose 30 patients of the
remaining patients referred to Barts BP Centre of
Excellence and analyzed their records in a similar
fashion (reference cohort).
BP Measurements
Clinic BP. Clinic BP was recorded according to estab-
lished guidelines4 using a validated monitor for clinical
use (Omron 705IT, Omron Corporation, Tokyo, Japan)
and an appropriately sized cuff. The lowest of at least
three readings was used as clinic BP.4
Home BP. Patients were instructed to conduct home BP
monitoring for between 4 and 7 days, immediately prior
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to clinic visits, with two readings in sequence in the
morning (1 hour premedication) and evening (at least
1 hour on either side of evening meal and medication).
The first day’s readings were discarded and all other
readings were averaged to provide home BP as per UK
national guidelines.4 Patients were given instructions to
use a validated monitor for home use and an appropri-
ately sized cuff.
Ambulatory BP. Daytime ABP was recorded using
validated monitors according to established guidelines.4
Biochemistry
Blood samples were sent to the Department of Clinical
Biochemistry at Barts Health NHS Trust as part of
routine monitoring, including serum creatinine (sCr),
estimated glomerular filtration rate (eGFR; by Chronic
Kidney Disease Epidemiology Collaboration equation
estimation), and total cholesterol/high-density lipoprotein
cholesterol ratio.
Echocardiography
Standard transthoracic echocardiographic views were
routinely obtained to determine interventricular septal
width (in diastole) as a measure of left ventricular
hypertrophy (upper limit of normal 12 mm).
MDI-HTN Algorithm
Our novel, hierarchical treatment algorithm was based
on four strata (Figure 1):
TABLE I. Sample of Available Formulations of Most Commonly Used Antihypertensive Medications From
Recommended and Other Classes With Minimum Tablet Size (Below Which Was Considered Fractional Tablet
Dosing) and Maximum Licensed or Recommended Dose26
Medication Class/Name Minimum Tablet Weight
Maximum Licensed
(Recommended) Daily Dose Alternative Formulation (Strength)
ACE inhibitor/ARB
Ramipril 1.25 mg 10 mg Liquid (2.5 mg/mL)
Lisinopril 2.5 mg 80 mg
Candesartan 2 mg 32 mg
Losartan 25 mg 100 mg Liquid (12.5 mg/mL)
CCB
Amlodipine 5 mg 10 mg
Felodipine 2.5 mg 20 mg
Nifedipinea 20 mg MR 90 mg MR Liquid (20 mg/mL)
Verapamil 40 mg (120 mg MR) 480 mg (480 mg MR) Liquid (40 mg/5 mL)
Diuretics
Indapamide 2.5 mg (1.5 mg MR) 2.5 mg (1.5 mg MR)
Bendroflumethiazide 2.5 mg 2.5 mg
Furosemide 20 mg 80 mg Liquid (20 mg/5 mL)
Torasemide 2.5 mg 5 mg
MRA
Spironolactoneb,c 25 mg 100 mgd Liquid 10 mg/5 mL
Eplerenoneb 25 mg 400 mgd
b-Blocker
Atenolol 25 mg 50 mg Liquid (25 mg/5 mL)
Bisoprolol 1.25 mg 20 mg
a-Blocker
Doxasozin 1 mg 16 mg
Terasozin 2 mg 20 mg
Centrally acting
Clonidine 0.025 mg 1.2 mg Transdermal 0.1–0.3 mg/d
Moxonidine 0.2 mg 0.6 mg
Vasodilators
Hydralazine 25 mg 100 mg
Isosorbide mononitrateb 10 mg (25 mg MR) 120 mg (120 mg MR)d
Glyceryl trinitrateb n/a 10 mgd Transdermal 5–15 mg/d
Tadalafilb 2.5 mg 10 mgd
Abbreviations: ACE, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; CCB, calcium channel blocker; MR, modified-
release; MRA, mineralocorticoid antagonist. aNifedipine (plain) is only available in the United Kingdom as capsules and therefore cannot reliably be
fractionally split. For the purposes of use of nifedipine MR (once-daily), doses are quoted for Adalat LA (as different versions of MR preparations may not
have the same clinical effect). bUnlicensed indication. cSpironolactone is unlicensed although recommended by United Kingdom guidelines 4.
dMaximum recommended dose established as the dose that our hypertension specialists would not increase above.
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 Solid formulations (tablets) of conventional guide-
line-recommended antihypertensive medications at
fractional doses (ie, at doses below the minimum
solid weight listed in the British National Formu-
lary26 achieved by halving/quartering tablets with a
tablet cutter).
 Liquid formulations of conventional guideline-
recommended antihypertensive medications at frac-
tional doses.
 Transdermal preparations of available antihypertensive
medications.
 Use of medications not licensed for hypertension and
not currently recommended by guidelines.
Starting stepped-care from step 1, prescribing clini-
cians were free to choose the most appropriate treat-
ment (with no stipulated order of medication class)
within each strata of this algorithm depending on the
individual patient and patient preference. Medication
classes that had previously caused intolerances were
re-used within the algorithm unless the patient described
a type 1 hypersensitivity allergy previously. Patients
were instructed not to continue taking medications that
caused unacceptable side effects and to document those
adverse reactions and effects on BP and contact our
center for further advice.
Statistical Analysis
Statistical analysis was performed using GraphPad
Prism v6 (La Jolla, CA) and P<.05 was considered
significant for all analyses. Data are presented as
meanstandard deviation unless otherwise specified.
The prespecified coprimary outcomes were change in
clinic and home BP after both 6 and 12 months of
follow-up. Changes in BP and medication parameters
over time were compared by repeated measures analysis
of variance with Dunnett’s post-hoc tests (to account for
multiple comparisons) for comparison to baseline (new
patient visit) and Bonferroni post-hoc tests (to account
for multiple comparisons) for comparisons between
timepoints. Categoric data were analyzed by Fisher’s
exact test.
RESULTS
Of the 786 new patients referred to Barts BP Centre of
Excellence during the period of study, 79 were identified
with MDI-HTN. Of these patients, 55 satisfied inclusion
and exclusion criteria, and reasons for noninclusion of
the remaining 24 are presented in Figure 2.
Patient demographics and baseline characteristics are
presented in Table II. Most MDI-HTN patients were
referred from primary care by a primary care physician
(40%, n=22) but significant proportions were initiated
by patients themselves (24%, n=13) or referred from
other nonspecialist secondary care physicians (36%,
n=20), which was significantly different to the reference
population (primary care, n=25; secondary care, n=5
[P<.01]). MDI-HTN patients were older (P<.001), more
likely to be female (P<.05), and of white European
ethnicity (P<.01) than the reference cohort.
There was a high burden of target organ damage
(Table III) (as measured by echocardiographic left
ventricular hypertrophy) in MDI-HTN patients (55%,
n=30), although this was not significantly different to
the reference cohort (P=.51). MDI-HTN patients had
similar levels of renal function measured by sCr (P=.57),
eGFR (P=.42), and nonfasting cholesterol profiles
(P=.47) to the reference population (Table III). A total
of 41% (n=23) and 16% (n=9) of MDI-HTN patients
had a coexisting diagnosis of gastroesophageal reflux
disease or an anxiety disorder, respectively. Other
diagnoses such as autoimmune diseases or diabetes
occurred at a frequency of <5%.
MDI-HTN patients were intolerant of numerous
medication classes and medicines and were prescribed
significantly less medicine than the reference cohort in
terms of number of medication classes (P<.001),
medications (P<.001), and WME (P<.001) at baseline
(Table II). A total of 22% (n=12) of MDI-HTN patients
were receiving no antihypertensive medications at
baseline, with 6% of MDI-HTN patients on fractional
tablet dosing (as defined by the novel algorithm) at
referral. No other MDI-HTN patients reported histor-
ical treatment with fractional doses prior to referral. In
addition, no patients in the reference cohort were on
fractional tablet dosing. At baseline, no patients in
either the MDI-HTN or reference cohort were on liquid
or transdermal formulations of antihypertensive medi-
cations. No patients were taking two drugs from within
the same class at baseline evaluation.
FIGURE 1. Barts multiple drug intolerances to anti-hypertensive
medications algorithm.
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While in the reference cohort there was a significant
change in clinic BP between referral and first clinical
review (1120/814 mm Hg, P<.01), this was not
apparent in MDI-HTN patients (110/18 mm Hg,
P=.74). At first clinical review, all patients had significant
uncontrolledBP, althoughMDI-HTNpatients hadhigher
clinic SBP (P<.001) and DBP (P=.06) values compared
with the reference cohort (15719/8813 mm Hg).
At 6-month follow-up on the novel MDI-HTN
treatment algorithm, MDI-HTN patients (n=55)
received 3.30.5 outpatient visits (including new
patient visit) and had initiated 2.9+1.7 algorithm-based
medication changes in the previous 6 months.
Clinic BP was reduced by 135/52 mm Hg (P<.05
for both) and home BP was reduced by 114/
83 mm Hg (P<.01 and P<.05, respectively) (Figure 3).
MDI-HTN patients were receiving more medications
(2.01.2) without increased WME (0.80.9) than
they were at baseline (P<.01 and P=not significant,
respectively) (Figure 4).
A total of 70% (n=39) of MDI-HTN patients were
prescribed a fractional tablet medication in order of
frequency: calcium channel blockers (CCBs; n=28),
angiotensin II receptor blockers (n=21), mineralocorti-
coid antagonists (n=21), central sympatholytic agents
(n=18), b-adrenoceptor blockers (n=10), thiazide-like
diuretics (n=8), and a-adrenoceptor blockers (n=4).
Examples of fractional dosing include amlodipine
2.5 mg daily, losartan 12.5 mg daily, spironolactone
6.25 mg daily, moxonidine 100 µg twice daily, atenolol
12.5 mg daily, bendroflumethiazide 1.25 mg daily, and
doxazosin 0.5 mg twice daily (Table I).
A total of 40% (n=22) of MDI-HTN patients were
prescribed a liquid formulation, with CCBs being
prescribed most commonly (91%, n=20), and smaller
proportions of patients were prescribed alternative
liquid medications, such as mineralocorticoid antago-
nists (9%, n=5), loop diuretics (5%, n=3), and
angiotensin-converting enzyme inhibitors (2%, n=1).
Examples of liquid formulations include nifedipine oral
solution (OS) 2 mg twice daily, spironolactone OS 5 mg
daily, furosemide OS 10 mg twice daily, and ramipril
OS 2.5 mg daily.
A total of 16% (n=9) of MDI-HTN patients were
prescribed a transdermal formulation of medication,
with 11% (n=6) for both transdermal clonidine and
glyceryl trinitrate (eg, clonidine TTS1 patch 2.5 mg
weekly or glyceryl trinitrate as Minitran patch 5 mg
daily). A total of 11% (n=6) of MDI-HTN patients were
prescribed a phosphodiesterase inhibitor (eg, tadalafil
FIGURE 2. Inclusion/exclusion of patients within cohort. BP indicates blood pressure; HTN, hypertension.
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2.5 mg daily). At 6 months, 22% (n=12) of MDI-HTN
patients were discharged to primary care for further
management, while active follow-up was continued in
the remaining 78% (n=43, two with missing data for the
following 6 months).
After a further 6 months of follow-up (total
12 months) on the novel MDI-HTN treatment algo-
rithm, MDI-HTN patients (n=41) received a further
1.50.9 outpatient visits and initiated a further 1.4+1.0
algorithm-based medication change in the previous
6 months. At 12-month follow-up (n=41), clinic BP
was reduced from baseline by 175/93 mm Hg
(P<.01, P<.05) and home BP was reduced by 115/
123 mm Hg (P<.01 for both) (Figure 3), while
patients were receiving 1.91.1 medications delivering
0.70.7 WME (P<.05 and P=not significant, respec-
tively) (Figure 4).
By 12 months of follow-up of the 41 MDI-HTN
patients, 98% (n=40) were prescribed a fractional tablet
medication in order of frequency: CCBs (n=26),
angiotensin II receptor blockers (n=20), mineralocorti-
coid antagonists (n=19), central sympatholytic agents
(n=14), b-adrenoceptor blockers (n=8), thiazide-like
diuretics (n=8), and a-adrenoceptor blockers (n=4). A
total of 78% (n=32) of MDI-HTN patients were
prescribed a liquid formulation, with CCBs being
prescribed most commonly (61%, n=25) and alternative
liquid medications, such as mineralocorticoid antago-
nists (17%, n=7), loop diuretics (10%, n=4), and
angiotensin-converting enzyme inhibitors (5%, n=2)
less commonly. A total of 49% (n=20) of MDI-HTN
patients were prescribed a transdermal formulation of
medication, with 37% (n=15) for transdermal clonidine
and 20% (n=8) for glyceryl trinitrate. A total of 20%
(n=8) of MDI-HTN patients were prescribed a phos-
phodiesterase inhibitor and 5% were prescribed a long-
acting organic nitrate. At 12 months, a further 12%
(n=5) of these MDI-HTN patients were discharged to
primary care for further management, while active
follow-up was continued in the remaining 88% (n=36).
A total of 9% (n=5) of the total MDI-HTN cohort
were entered into clinical trial programs of device-based
therapies for hypertension within 12 months of follow-
up.
DISCUSSION
Antihypertensive medication prevents major cardiovas-
cular events in patients with hypertension27 but popu-
lation-level control of BP in treated hypertensive
patients is suboptimal.5 In this study, we described a
cohort of patients who were unable to take many classes
of antihypertensive medications at conventional doses.
We developed and introduced a novel treatment algo-
rithm to enable patients to receive more individualized
medicines and significantly reduce BP up to 1 year of
follow-up without increasing WME. The prevalence of
MDI (to any medications) in the general population is
2% to 5%,28,29 although in our center over a 24-month
period, >10% of all referrals were of patients with
MDI-HTN, who on average declared intolerances to
five antihypertensive classes and seven antihypertensive
medications prior to referral. Recognizing that there
are no clinical trials in such groups to provide a
high-quality, evidence-based approach, we developed a
treatment stratagem around four evidence-based
observations.
Firstly, ADRs to most standard antihypertensive
medication classes are dose-dependent.30 We reasoned
that prescribing medications at minimal doses (ie,
fractional dosing by splitting lowest weight tablet for
each medication) and not titrating above usual mainte-
nance doses would allow patients to tolerate medication
classes they had previously stopped taking while at
higher doses.
Secondly, combination of medications at low doses
(between two and four medication classes) has been
demonstrated to be additive and achieve a greater BP-
lowering effect than increasing monotherapy.30,31 Thus,
we reasoned that by keeping medications at low doses to
reduce the chance and/or severity of ADRs and by
combining different classes we could still achieve
meaningful BP reduction by targeting different physio-
logical regulatory systems involved in cardiovascular
homeostasis.
Thirdly, pharmaceutical excipients, required for man-
ufacture of medications as tablets or capsules (such as
lactose and silica.), account for 90% of the weight
of solid medication formulations32 and are associated
with (especially gastrointestinal) ADRs33,34 that could
possibly explain pharmacodynamically unpredictable
TABLE II. Baseline Demographics, Hemodynamic
Values, and Medication Use in MDI-HTN and
Reference Population
Characteristics Reference MDI-HTN
No. (female) 30 (13) 55 (40)
Age, y 4713 669
White-European ethnicity, No. 10 50
Referral mode, No.
Primary care 25 22
Secondary care 5 20
Self-referred 0 13
Referral office BP, mm Hg
SBP 16820 17725
DBP 9613 9516
Intolerances, No.
Classes 0.20.4 5.32.1
Medications 0.20.4 7.63.6
Prescribed medications, No.
Classes 3.51.7 1.41.1
Medications 3.61.8 1.41.1
WME 2.71.3 0.80.8
Abbreviations: BP, blood pressure; DBP, diastolic blood pressure;
MDI-HTN, multiple drug intolerances to antihypertensive medication;
SBP, systolic blood pressure; WME, whole medicine equivalent. Data
are expressed as meanstandard deviation.
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reactions reported by patients to unrelated classes of
antihypertensive medications. In practice, few excipients
are totally inactive or inert in vivo. We reasoned that
providing medications in liquid and/or transdermal
patch formulation might obviate some of these prob-
lems. Transdermal patches can also offer benefits over
oral formulations in terms of ease of use, reduce
requirements of dosing intervals (eg, once-daily to
once-weekly), avoiding first-pass effects (less interac-
tions), as well as avoidance of high maximum plasma
levels with rapid changes in drug concentration that
may give rise to ADRs that lead to intolerances.
Lastly, we reasoned that repurposing of medications
with licensed indications apart from hypertension, such
as phosphodiesterase inhibitors and long-acting organic
nitrates, which lower BP in small clinical trials,35,36
could be appropriate in trials of therapy if all else fails.
Additionally, we rechallenged patients with medications
from the same classes to which they had declared
intolerances (but not in cases of type 1 hypersensitivity).
Switching within the same class may possibly avoid
ADRs in view of the structural differences between
similar agents. This strategy for antihypertensive
medications has not been largely studied, in comparison
to lipid-lowering medications for which intraclass
switching is well-established.37
Adoption of our stratified medicines approach was
associated with large reductions in both clinic and out-
of-office BP (home) that were sustained for 12 months
in our cohort. These reductions were related to changes
in medications that resulted in overall increases in
medication classes by approximately 50% per patient
but without increasing overall WME; ie, patients were
taking more medications but at lower doses than previ-
ously. The magnitude of BP reduction at 12 months was
similar to that predicted from combining two medica-
tions from different classes at half-standard dose (usual
maintenance dose, which is <MLD for most medica-
tions) of approximately 18/8 mm Hg, using an approx-
imated baseline BP of 180/95 mm Hg.27 This is a
significant reduction in BP, which, if sustained, would
lead to large reductions in relative risk of both stroke
and ischemic heart disease events by 40% to 60%.27 In
addition, others have demonstrated similar magnitudes
of BP reduction in nonselected referral patients (ie, not
specific MDI-HTN patients) to hypertension specialist
FIGURE 3. Clinic and home blood pressure (BP) at baseline and up to 12 months of follow-up. Data are expressed as meanstandard
deviation (n=55 at 0 and 6 months; n=41 at 12 months). Significance shown as *P<.05 and **P<.01 for Dunnett’s post-hoc test comparison to
0 months following one-way analysis of variance. DBP indicates diastolic blood pressure; SBP, systolic blood pressure.
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services at 1 year without increasing overall prescribed
medication items.38 While it has previously been
demonstrated that adherence is less likely with increas-
ing prescription item numbers,39 at least in this cohort
of patients with multiple previous medication intoler-
ances preventing adherence to antihypertensive therapy
at conventional doses, increasing the number of pre-
scription items was associated with improvement in BP.
However, our cohort was followed for only a maximum
of 12 months and therefore we cannot assume that the
responses we have seen will be maintained for longer
periods, as the development of medication intolerance,
eg, statin-induced myopathy, can occur up to several
years after initiation.40
In comparison to our randomly selected reference
cohort, MDI-HTN patients were almost exclusively of
white European ethnicity, which is different than the
commonly described ethnicities (black African or black
Caribbean) associated with resistant hypertension, and
were predominantly female, which is the same as for
resistant hypertension.41 Our study was not able to
discern the reasons for these associations. MDI-HTN
patients exhibited higher baseline BP and, as expected,
fewer prescribed medications at baseline review. It is
perhaps surprising that this did not lead to significantly
more cardiovascular target organ damage in the MDI-
HTN cohort, although we were unable to report on left
ventricular mass indexed to body surface area, as this is
not routinely reported in our cardiovascular department
and we were unable to retrospectively calculate this
from two-dimensional echocardiography dimensions
because of lack of robust anthropometric data in this
dataset. While in the reference population there
appeared to be a regression-to-mean or Hawthorne
phenomenon between referral and first-review clinic
BP, this was not apparent in the MDI-HTN cohort.
One possibility is that in patients without medication
intolerance, referral to a specialist center was associated
with improved adherence and therefore lower BP on
first review, although this was not ascertainable in this
study.
We demonstrated a four-fold higher prevalence of
diagnosed anxiety disorder in our MDI-HTN patients,
which is in concordance with previous research in
patients with MDI-HTN42 and patients with MDI to
FIGURE 4. Medication use at baseline and up to 12 months of
follow-up. Data are expressed as meanstandard deviation (n=55 at
0 and 6 months; n=41 at 12 months). Significance shown as *P<.05
and **P<.01 for Dunnett’s post-hoc test comparison to 0 months
following one-way analysis of variance. WME indicates whole
medication equivalent.
TABLE III. Cardiovascular Risk and Comorbidities
in MDI-HTN and the Reference Population
Medical Indices Reference (n=30) MDI-HTN (n=55)
Target organ damage
LVH, No. (%) 14 (47) 30 (55)
Renal indices
sCr, lmol/L 9135 8731
eGFR, mL/min 7019 7419
Lipid indices
TC:HDL ratio 3.41.2 3.60.9
Comorbidities, No. (%)
GERD 3 (10) 23 (42)
Anxiety disorder 1 (3) 9 (16)
Diabetes mellitus 5 (17) 2 (4)
Autoimmune disease 4 (13) 2 (4)
Abbreviations: eGFR, estimated glomerular filtration rate; GERD,
gastroesophageal reflux disease; LVH, left ventricular hypertrophy;
MDI-HTN, multiple drug intolerances to antihypertensive medication;
sCr, serum creatinine; TC:HDL, total cholesterol:high-density
lipoprotein cholesterol.
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other medications21 that suggested increased prevalence
of anxiety and panic disorder, depressive, and somatiz-
ing traits. These traits may serve to explain some of the
nonpharmacologically expected and nonidiosyncratic
ADRs that some patients describe, possibly the result
of increased propensity to a nocebo response43 or
increased likelihood to report worse severity of ADRs.44
Importantly, there is no recommended management
plan for patients in whom psychological explanations of
ADRs are identified.21,43 In addition, there are other
possible organic explanations for apparently non–drug-
related ADRs such as mitochondrial toxicity45 or some
patients not tolerating systemic BP reduction because of
a lack of effective cerebral autoregulation causing
reduced cerebral blood flow.46 Gastroesophageal reflux
disease was four-fold more common in MDI-HTN
patients and may explain why some of these patients
were able to tolerate more antihypertensive medication
classes (in liquid or transdermal formulations) than
previously. This may be related to excipients or
physiochemical properties of solid dose formulations.
Despite the success of our algorithm, a small subset of
patients were enrolled into clinical trials of device-based
therapy of hypertension, reflecting that some patients
were not able to tolerate any medications within our
algorithm or that the amount they could tolerate was
insufficient to achieve BP control necessitating further,
experimental approaches.
STUDY LIMITATIONS
Limitations of our study include the retrospective nature
of the data extraction and collection from electronic and
paper patient records and limited length of follow-up,
which restricts the ability to draw firm conclusions on
future CV risk. Furthermore, we were unable to extract
or locate all information relating to previous doses and
reasons for patient-specific individual medication intol-
erances from the patient records and can therefore not
comment on proportions of patients with type 1
hypersensitivity and pharmacologically expected or
unusual ADRs or determine whether pharmaceutical
or pharmacologic (or possibly psychological) mecha-
nisms were responsible for the beneficial effects on BP
lowering. We did not confirm adherence to prescribed
medications using urine or plasma TDM techniques as
our patients had declared overt nonadherence to previ-
ously taken medications and therefore we cannot
exclude BP reduction attributable to the Hawthorne
effect of regular medical interaction rather than
increased, tolerated pharmacotherapy. Patients with
MDI-HTN probably exhibited higher motivation levels
in relation to their CV health given that a substantial
proportion self-initiated referral to our service.
In addition, we recognize the imprecise nature of
fractional tablet dosing as it cannot be guaranteed that
tablets split exactly into half/quarter segments and that
some patients also struggled to manage the tablet cutter
because of advanced age or concomitant osteoarthropa-
thy. Furthermore, it is clear that undertaking such a
treatment algorithm involves multiple points of contact
with the clinician and is thus expensive from this
perspective as well as entailing use of higher-cost liquid
and patch formulations compared with standard off-
patent, generic tablets. However, despite these limita-
tions, the demonstrable BP reduction is encouraging and
our patients gave positive feedback on this novel
approach. We did not routinely use ABP to monitor
response to medication changes and therefore we may
have missed important pharmacodynamic responses to
the use of nonconventional formulations/posology such
as liquid nifedipine. Finally, we did not attempt to
address the mechanisms of medication intolerance and
we accept that in many instances these are unusual and
inexplicable and could be linked to personality traits.
However, our focus was on providing a management
strategy for these often desperate, high-risk patients
whose primary care practitioners and other specialists
had run out of options to improve their BP and as such
we were unable to retrospectively compare our findings
with a control cohort of MDI-HTN patients who
persisted with standard care.
CONCLUSIONS
A total of 10% of referred patients to a specialist BP
center had MDI-HTN, resulting in insufficient pharma-
cotherapy and significant uncontrolled hypertension. A
novel treatment algorithm designed for the management
of patients with MDI-HTN, based on fractional tablet,
liquid, transdermal antihypertensive medications and
the unlicensed use of vasoactive medications was
associated with significant increased tolerability of
medication classes with concomitant significant BP
reduction. Further, prospective studies are required to
determine whether this strategy has long-term benefits
on BP and cardiovascular morbidity in this difficult-to-
treat population.
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